Jiangsu Hengrui Medicine has been granted a patent for an interleukin 15 (IL-15) protein complex. The complex consists of soluble fusion proteins (I) and (II), where (I) is an IL-15 polypeptide and (II) is an IL-15Ra polypeptide. The proteins form disulfide bonds through specific amino acid substitutions. The IL-15 protein complex has potential applications in tumor therapy. GlobalData’s report on Jiangsu Hengrui Medicine gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Jiangsu Hengrui Medicine, Cancer treatment biomarkers was a key innovation area identified from patents. Jiangsu Hengrui Medicine's grant share as of September 2023 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for il-15 protein complex for tumor therapy
A recently granted patent (Publication Number: US11717559B2) discloses a novel IL-15 protein complex and its production method. The complex consists of two soluble fusion proteins, namely soluble fusion protein (I) and soluble fusion protein (II). Soluble fusion protein (I) contains an IL-15 polypeptide, while soluble fusion protein (II) contains an IL-15Ra polypeptide. The patent claims that the soluble fusion protein (I) has a cysteine substitution at a specific position corresponding to residue Q48, V49, L52, or E53 of the IL-15 polypeptide sequence. Similarly, the soluble fusion protein (II) has a cysteine substitution at a specific position corresponding to residue A37, G38, S40, or L42 of the IL-15Ra polypeptide sequence. The two fusion proteins are linked by a disulfide bond formed by the cysteine residues.
According to the patent, at least one of the soluble fusion proteins (I) and (II) can be covalently linked to an Fc fragment. The soluble fusion protein (I) can have a specific amino acid sequence (SEQ ID NO: 2) and may have cysteine substitutions at positions L52 or E53 of the IL-15 polypeptide sequence. The soluble fusion protein (II) can have cysteine substitutions at positions A37, G38, or S40 of the IL-15Ra polypeptide sequence, or at position S40 of the IL-15Ra polypeptide sequence when the soluble fusion protein (I) has a cysteine substitution at position L52. Additionally, the soluble fusion protein (II) can include an Fc fragment, with the IL-15Ra polypeptide attached to the N-terminus of the Fc fragment. The Fc fragment can have a specific amino acid sequence (SEQ ID NO: 9).
The patent also covers isolated DNA vectors containing the nucleic acids encoding the IL-15 protein complex, as well as isolated host cells containing these DNA vectors. A method for preparing the IL-15 protein complex is described, involving culturing the host cells under suitable conditions for expression and purification of the complex. Furthermore, the patent includes a pharmaceutical composition comprising the nucleic acids encoding the IL-15 protein complex, along with a pharmaceutically acceptable excipient, diluent, or carrier.
In summary, this granted patent introduces a novel IL-15 protein complex and its production method. The complex consists of two soluble fusion proteins, with specific amino acid sequences and cysteine substitutions. The patent covers various aspects of the complex, including its composition, production, and pharmaceutical applications.
To know more about GlobalData’s detailed insights on Jiangsu Hengrui Medicine, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
